Now turn the call over to Sandy Martin, Three Part Advisors ... transition continues to impact our revenues. For the full yeat 2025 we anticipate that the Volvo transaction will reduce revenue ...

Also present at the event were GD Holdings group executive chairman Datuk Seri Yeat Sew Chuong ... companies from the Chinese city. Wong said phase one of the project will encompass 40 units ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

Mineralys Therapeutics' lorundrostat shows promising Phase 3 results in treating resistant hypertension, with 9.1 mmHg blood ...

LoM total cash costs fall to $511/oz of 3PE+Au in the PEA for the Phase 3 expansion. This compares with a near-multiyear low basket spot price of $1 205/oz of 3PE+Au, as at February 17.

ITM, a pioneer in radiopharmaceuticals, said it will submit its first drug for approval after reporting the therapy halted ...

During the completed Phase 3 clinical trial, the 5-year survival rate of the target patient population increased to 73% when patients were treated with Multikine vs 45% for control patients who ...